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Summary
Angiogenesis inhibitors, such as TNP-470 and the nontoxic HPMA copolymer-TNP-470 (caplostatin), are emerging as a
class of anticancer drugs. We report that TNP-470 and caplostatin inhibit vascular hyperpermeability of tumor blood
vessels as well as that induced in mouse skin by different mediators. Treatment with TNP-470 or angiostatin for 3 days
was sufficient to reduce permeability of tumor blood vessels, delayed-type hypersensitivity, and pulmonary edema induced
by IL-2. TNP-470 also inhibited VPF/VEGF-induced phosphorylation of VEGFR-2, calcium influx, and RhoA activation in
endothelial cells. These results identify an activity of TNP-470, that of inhibiting vessel hyperpermeability. This activity
likely contributes to TNP-470’s antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer
and inflammation.S I G N I F I C A N C E
It has long been known that the blood vessels supplying tumors and sites of inflammation are hyperpermeable to plasma and
plasma proteins. Our study shows that several inhibitors of angiogenesis, TNP-470, its novel nontoxic polymeric conjugate caplo-
statin, and angiostatin, reduce plasma macromolecule extravasation from the pathologically hyperpermeable vasculature supply-
ing tumors and inflammatory sites, and also from blood vessels rendered hyperpermeable by three vascular permeabilizing media-
tors, VEGF, PAF, and histamine. These inhibitors also reduced edema in tumors and pulmonary edema induced by IL-2 therapy and
so could be useful as adjuvant therapy for tumors, inflammatory conditions, or complications of chemotherapy or immunotherapy.
Our results describe a novel mechanism of action for TNP-470 and possibly other endogenous proteins with antiangiogenic activity.Introduction
Angiogenesis, the generation of new blood vessels from preex-
isting microvasculature (Folkman and Kalluri, 2003), is regu-
lated by a number of different growth factors (Matsumoto and
Claesson-Welsh, 2001). Prominent among these is the vascular
endothelial growth factor (VEGF) family of proteins (Neufeld et
al., 1999). VEGF family members exert their activities by bind-
ing to three structurally related receptor tyrosine kinases, VEGF
receptor (VEGFR)-1, -2, and -3. Neuropilins, heparan-sulfated
proteoglycans, cadherins, and integrins serve as coreceptors
for certain but not for all VEGF family proteins (Neufeld et al.,
1999). VEGF-A exists in several different isoforms (VEGF121,
VEGF165, VEGF189), each of which has unique biological and
biochemical properties (Feng et al., 2002). The most prominent
VEGF-A isoform, VEGF165, was initially discovered as a tumor-
secreted protein that increased vascular permeability and was
named vascular permeability factor (VPF) (Senger et al., 1983).
Subsequently, VPF was shown to promote endothelial cell (EC)
proliferation and migration and was renamed vascular endo-
thelial growth factor (VEGF) (Ferrara and Henzel, 1989). As far
as is known, VEGF165, here referred to as VPF/VEGF, exerts
most of its biological activities (EC proliferation, migration, sur-CANCER CELL : MARCH 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIER INvival, and permeability) by activating VEGFR-2 (Claesson-
Welsh, 2003).
While EC proliferation is an important component of angio-
genesis (Koch et al., 1994), VPF/VEGF has relatively weak mi-
togenic activity compared to other factors such as basic fibro-
blast growth factor (bFGF). However, VPF/VEGF is a potent
vascular permeabilizing factor, and it has been known for some
time that tumors and other forms of pathological angiogenesis
are preceded and/or accompanied by enhanced vascular per-
meability (Dvorak, 2002; Folkman and Kalluri, 2003). In tumors
that secrete VPF/VEGF, microvascular hyperpermeability re-
sults in extravasation of plasma and plasma proteins, leading
to edema and deposition of an extravascular fibrin gel (Feng et
al., 2000). This gel supports new blood vessel growth and the
laying down of mature connective tissue stroma. Vascular
hyperpermeability and fibrin deposition are also found in other
examples of pathological angiogenesis mediated by VPF/
VEGF, such as wound healing, arthritis, and psoriasis (Dvorak,
2002; Feng et al., 2000).
Given the prominence of vascular permeability in pathologi-
cal angiogenesis, we investigated whether known angiogen-
esis inhibitors had an effect on vascular permeability. TNP-470,
a synthetic analog of fumagillin, had been shown to block angi-C. DOI 10.1016/j.ccr.2005.02.007 251
A R T I C L Eogenesis (Ingber et al., 1990) and to inhibit tumor growth in
several preclinical studies (Kragh et al., 1999) as well as in clin-
ical trials (Milkowski and Weiss, 1999). TNP-470’s clinical utility
was limited by neurotoxicity, a complication that has recently
been overcome by conjugating it to a water-soluble N-(2-hydrox-
ypropyl)methacrylamide (HPMA) copolymer (Satchi-Fainaro et
al., 2004). At present, the only known molecular target of TNP-
470 is methionine aminopeptidase-2 (MetAP2) (Griffith et al.,
1997), a cytoplasmic metalloenzyme responsible for removing
the N-terminal methionine from nascent proteins. However, it
is unclear how inhibition of this ubiquitously expressed protein
affects TNP-470’s action on EC proliferation (Ingber et al.,
1990). To date, there is no evidence for TNP-470 binding an
extracellular receptor.
TNP-470’s effect on tumor growth has been thought to result
mainly from its effects on EC proliferation (Abe et al., 1994).
However, we demonstrate here that both TNP-470 and its non-
toxic high-molecular weight HPMA copolymer conjugate,
caplostatin, strikingly inhibit the vascular permeability-inducing
effects of VPF/VEGF as well as that of platelet-activating factor
(PAF) and histamine. TNP-470 inhibited extravasation of plasma
proteins across microvascular endothelium in response to VPF/
VEGF and other mediators in vivo as well as signaling path-
ways mediated through VEGFR-2, Ca2+ influx, and RhoA acti-
vation on cultured endothelium. In addition, we show that TNP-
470 inhibits the vascular hyperpermeability found in tumors
and in delayed-type hypersensitivity (DTH) reactions, as well
as in the pulmonary edema induced by interleukin-2 (IL-2). We
also show that angiostatin, another angiogenesis inhibitor
(O'Reilly et al., 1994), inhibits vascular permeability. Taken to-
gether, we demonstrate a mechanism by which TNP-470 and
at least one other inhibitor antagonizes angiogenesis.
Results
TNP-470, caplostatin, and angiostatin reduce
microvessel permeability
The Miles assay was used to determine whether TNP-470,
caplostatin, or angiostatin affected vascular permeability, a
prominent early feature of pathological angiogenesis (Figure 1).
Evans blue dye was injected i.v., and immediately thereafter
several vascular permeability-inducing agents (VPF/VEGF, PAF,
histamine) were injected into the shaved flank skin of SCID
mice. Evans blue dye binds to plasma proteins and therefore
extravasates along with them at sites of increased permeability
(Miles and Miles, 1952). VPF/VEGF-induced extravasation of
Evans blue dye was strikingly inhibited (by ~70%) in mice
treated for at least 24 hr with either TNP-470 or caplostatin
(Figures 1A and 1B). Angiostatin treatment for 5 days also in-
hibited the vascular permeabilizing effects of VPF/VEGF but to
a lesser extent (40%). In contrast, Herceptin and thalidomide,
angiogenesis inhibitors that act indirectly on EC (Kerbel and
Folkman, 2002), did not affect VPF/VEGF-induced vascular
permeability (Figures 1A and 1B).
To determine whether the antipermeabilizing effects of TNP-
470, caplostatin, and angiostatin were specific to VPF/VEGF,
we tested their ability to inhibit the permeability-enhancing ef-
fects of PAF and histamine. TNP-470 and caplostatin reduced
Evans blue dye accumulation induced by PAF and histamine
by 75% and 80%, respectively; treatment with angiostatin re-
duced PAF- and histamine-induced permeability by 37% and252Figure 1. TNP-470 prevents vascular permeability in mouse skin capillaries
Vessel permeability was assessed by the Miles assay. Mice were pretreated
systemically with saline, methyl cellulose, Herceptin, thalidomide, angio-
statin, TNP-470, or caplostatin for 3–5 days and were then anesthetized and
administered Evans blue i.v. (10 min) followed by intradermal injection of
PBS (50 l) and VPF/VEGF (50 ng in 50 l) for 20 min.
A: Diminished dye is observed in mice treated with free or conjugated TNP-
470 and angiostatin compared to treatment with thalidomide, Herceptin,
or methyl cellulose and saline.
B: Skin was excised, and extracted dye contents were quantified by meas-
uring at 620 nm. Data are expressed as mean ± SE.
C: Quantification of dye extracted from PBS (black columns)-, VEGF (gray
columns)-, PAF (white columns)-, and histamine (striped columns)-induced
permeability sites following treatments with TNP-470, caplostatin, angio-
statin, or saline. Data are expressed as mean ± SE.51%, respectively (Figure 1C). Of interest, TNP-470 and cap-
lostatin also blocked the low-level permeability induced by in-
tradermal injections of PBS (Figure 1C). These results indicate
that angiogenesis inhibitors inhibit vascular permeability in-
duced by mediators that are thought to act by different mecha-
nisms and through different signaling pathways.
Comparisons of Miles assay results among different groups
of animals are only valid if blood flow and volumes remain
equivalent. To rule out the possibility that TNP-470’s action on
permeability was attributable to an effect on blood flow, we
injected Evans blue dye i.v. into TNP-470-treated and un-
treated animals and collected skin samples 5 min later for dyeCANCER CELL : MARCH 2005
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Evans blue there is very little extravasation of dye, so the vast
majority is contained within the blood vasculature; thus, ex-
tracted dye provides a measure of blood volume and flow (H.
Zeng and H.F.D., unpublished data). We found no significant
difference between control and TNP-470-treated groups (0.004 ±
0.0001 and 0.005 ± 0.0002, respectively). If TNP-470 had af-
fected skin blood flow, for example, by constricting microves-
sels, we would have expected a reduction in Evans blue dye
accumulation.
TNP-470 decreases microvascular permeability
in DTH reactions
DTH reactions are characterized by vascular hyperpermeability
that is thought to be mediated by VPF/VEGF (Brown et al.,
2000; Colvin and Dvorak, 1975). We therefore determined
whether TNP-470 would also inhibit the edema characteristic
of these reactions. DTH reactions in C57Bl/6J mice sensitized
with oxazolone and treated with TNP-470 exhibited signifi-
cantly reduced erythema and ear swelling as compared with
control mice at 24 and 48 hr (p < 0.01; Figures 2A and 2B).
No differences were found in the thickness of ears that were
sensitized with the vehicle, but not challenged with oxazolone
(Figure 2A). Histology confirmed the reduced swelling and
showed that the inflammatory cell infiltrate was also reduced
in TNP-470-treated mice (Figure 2C).
TNP-470 decreases pulmonary edema induced by IL-2
Patients with metastatic renal cell carcinoma and malignant
melanoma sometimes respond to IL- 2, but treatment with IL-2
is often limited by the development of systemic edema (Berthi-
aume et al., 1995). We therefore sought to determine whether
TNP-470 could prevent this adverse side effect using an IL-2-
induced pulmonary edema mouse model (Figure 3). As ex-
pected, IL-2-treated mice developed edematous lungs with
wet weights 2.5× normal (419.4 ± 50.4 mg); also, histology re-
vealed severe congestion and edema with intraalveolar fibrin
deposits as well as perivascular and peribronchial mononu-
clear cell infiltrates. By contrast, the lungs of mice treated with
TNP-470 remained normal in weight (170.2 ± 10.1 mg versus
177.8 ± 12.1 mg in control mice) and had normal histology.
The improvement in lung edema could not be attributed to a
generalized toxic effect of TNP-470, as over the 3 day period
of treatment body weight did not decline.
TNP-470 inhibits tumor blood vessel hyperpermeability
We next studied the effects of TNP-470 on tumor vessel per-
meability. We used six tumor cell lines whose expression of
VPF/VEGF in vitro had been shown to differ widely and whose
growth in vivo was inhibited to different extents (60%–95%) by
TNP-470 (Figure 4A). Treatment with TNP-470 or caplostatin
or with angiostatin in tumor-bearing mice inhibited Evans blue
extravasation, but to different extents in different tumors:
A2058 melanoma (p < 0.03 versus control), murine Lewis lung
carcinoma (LLC) (p < 0.05), MCF-7 breast carcinoma (p < 0.04),
MDA-MB-231 breast carcinoma (p < 0.05), and BXPC3 pancre-
atic adenocarcinoma (p < 0.04) by 40%–90% compared to
control tumors treated with saline (Figure 4B). Interestingly,
none of the drugs inhibited Evans blue extravasation into U87
glioblastomas (Figure 4B). A VPF/VEGF dose response was
used in a modified Miles assay to test the effect of VEGFCANCER CELL : MARCH 2005Figure 2. TNP-470 decreased ear swelling in DTH reactions elicited by oxa-
zolone
DTH reactions were induced in the ear skin of C57Bl/6J mice using oxazo-
lone challenge.
A: Ear swelling is expressed as the increase (m) over the original ear
thickness in micrometers. Mice treated with TNP-470 (red squares) showed
a significantly decreased ear swelling (p < 0.01) 24 hr after challenge as
compared with saline-injected challenged mice (green circles). Control
left ears treated with vehicle alone in both groups showed no swelling
(blue diamonds and black triangles). Data are expressed as mean ± SE.
B: Macroscopically visible increase of ear swelling and erythema in control
mice (left panel) as compared with TNP-470-treated mice (right panel) at
24 hr after oxazolone challenge.
C: H&E staining shows increased extravasation of infiltrate into the extracel-
lular matrix in control mice compared to TNP-470-treated mice, and arrows
mark lymphatics (see arrows).secreted from the tumor and the ability of TNP-470 to inhibit
the permeability induced. Control saline-treated mice showed
a dose-response correlation between increasing VPF/VEGF in-
jection and dye accumulation, up to saturation (Figure 4C).
TNP-470-treated mice showed inhibition of permeability up to
25 ng VPF/VEGF but, above that dose, TNP-470 lost its effec-
tiveness in inhibiting permeability and dye accumulation (Fig-
ure 4C).
We also measured the levels of VPF/VEGF in U87 glioblas-
toma and A2058 melanoma tumor-bearing mice. VPF/VEGF
levels in A2058 melanoma tumors were measured at 20 pg/
100 mg and in U87 glioblastomas at 3192 ± 762 pg/100 mg.253
A R T I C L EFigure 3. TNP-470 prevents IL-2-induced pulmonary edema
A: Mice were pretreated with saline or TNP-470 for 3 days and then in-
jected with IL-2 for 5 days. Lungs from euthanized mice were dissected
and weighed. Data are expressed as mean ± SE.
B: IL-2-induced pulmonary edema led to a massive thickening of the alve-
olar wall by extravasation of plasma proteins, generation of extracellular
matrix, and cellular infiltration. Pretreatment with TNP-470 significantly re-
duced these effects.254Figure 4. TNP-470 reduces tumor blood vessel permeability
A: VEGF levels in conditioned media of several cell lines. The growth of all
tumors tested for permeability in B is known from the literature to be inhib-
ited by TNP-470, as shown in the right column of the table. References are
as follows: 1, Satchi-Fainaro et al. (2004); 2, McLeskey et al. (1996); 3, Ya-
maoka et al. (1993); 4, R.S.-F., A.E. Birsner, and J.F., unpublished data; 5,
Takamiya et al. (1994).
B: Mice bearing LLC, A2058 melanoma, MCF-7 breast carcinoma, MDA-
MB-231 breast carcinoma, BXPC3 pancreatic adenocarcinoma, or U87 gli-
oblastoma were treated with saline (100%), TNP-470 (black columns),
caplostatin (gray columns), or angiostatin (white columns; only LLC, A2058,
and U87) for 3–5 days. Evans blue dye was injected, and after 10 min tu-
mors were excised and weighed, and dye content per 100 mg tumor tissue
was quantified at 620 nm. For each tumor, control group (saline) was de-
termined as 100% permeability. Tumor vessel permeability was inhibited in
all tumors except U87 glioblastoma. Data are expressed as mean ± SE.
C: C57Bl/6J mice were treated with TNP-470 (30 mg/kg/day s.c. for 3 days)
or with saline and injected with Evans blue i.v. (10 min), followed by injec-
tion with VEGF intradermally at different concentrations. Skin punch biop-
sies were collected, and extracted dye in formamide was read at 620 nm.
Control saline-treated mice showed a dose-response correlation between
increasing VEGF injection and dye accumulation, up to saturation. TNP-
470-treated mice showed inhibition of permeability up to 25 ng, but above
that dose, TNP-470 lost its effectiveness in inhibiting permeability and dye
accumulation.Differences in vascular permeability could be affected by
vessel number. Therefore, we determined whether TNP-470,
caplostatin, or angiostatin had an effect on vessel density in
mice implanted with the various tumor types. Following treat-
ment with free or conjugated TNP-470 (for 3 days) or angio-
statin (for 5 days), we found no significant difference in vessel
density from control animals as determined by immunohisto-
chemical staining for smooth muscle actin (SMA), proliferating
cell nuclear antigen (PCNA), or CD31 staining in A2058 mela-
noma or U87 glioblastoma tumor models. CD31 staining of
TNP-470, caplostatin, angiostatin, and untreated mice showed
no difference in microvessel density in A2058 (76 ± 12, 90 ±
23, 65 ± 17, and 70 ± 14 microvessels/mm2 ± standard error,
respectively) or U87 glioblastoma (108 ± 24, 120 ± 13, 105 ±
15, and 118 ± 30 microvessels/mm2 ± standard error, respec-
tively). From this, we conclude that differences in permeability
cannot be attributed to changes in vessel number or vessel
density. Thus, the effect of TNP-470 on VPF/VEGF-induced
permeability occurs without any effect on vessel number or
density (vascular proliferation).
TNP-470 does not affect the structure of vesiculo-
vacuolar organelles or of interendothelial junctions
Plasma proteins have been reported to extravasate from the
microvasculature by way of caveolae, fenestrae, and interen-
dothelial cell gaps, and especially through vesiculo-vacuolar
organelles (VVOs), a recently described structure in the endo-
thelium of normal venules and of some tumor vessels (reviewed
in Feng et al., 1996). Using transmission electron microscopy,
we found that TNP-470 had no effect on microvascular struc-
ture (Figures 5A–5D). VVOs were normal with respect to fre-
quency and size, interendothelial cell junctions were normally
closed, and fenestrae remained rare. Intravenously adminis-
tered ferritin extravasated from VPF/VEGF-injected sites viaCANCER CELL : MARCH 2005
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lial junction structures
A–D: Venule EC in mice injected systemically with buffer (A and B) or TNP-
470 (C and D). Interendothelial cell junctions (A and C) are normally
closed, and vesiculo-vacuolar organelles (VVOs) are normal (B and D) in
both sets of animals. There is minor leakage of intravenously injected circu-
lating ferritin (B, small particles, some of which are in the lumen and the
extravascular space) via VVOs (arrow marks a ferritin-containing vesicle).
Leakage was reduced in the TNP-470-treated set (C and D).
E–H: Venule EC in mice injected locally with VPF/VEGF and systemically
with buffer (E and F) or with TNP-470 (G and H). In both sets of mice, interen-
dothelial cell junctions are normally closed (E and G), and VVOs are nor-
mal. Intravenously injected ferritin is seen to be extravasating through VVO
vesicles (F, arrows) but to a lesser extent in TNP-470-treated mice (G and
H). L, vascular lumen; p, pericyte. Scale bars, 200 nm.VVOs as expected, and treatment with TNP-470 reduced such
extravasation (Figures 5F and 5H). Small amounts of ferritin
were also found in the VVOs of uninjected skin and in those of
skin injected with buffer (Figure 5B) in untreated animals, and
this was reduced in mice treated with TNP-470 (Figure 5D).
Interendothelial cell junctions remained normally closed in all
conditions tested. We conclude, therefore, that the antiperme-
ability effect of TNP-470 is functional and not structural.
The effect of TNP-470 on interendothelial junction proteins
was tested. Cultured bovine capillary EC (BCE) treated with or
without TNP-470 (1 ng/ml) exhibited no differences in expres-
sion levels or distribution of occludin, claudin, ZO-1, β-catenin,
and VE-cadherin (data not shown).
TNP-470 inhibits VPF/VEGF-induced VEGFR-2
phosphorylation, EC proliferation, Ca2+ influx,
and MAPK phosphorylation
VPF/VEGF is thought to achieve its multiple effects on vascular
endothelium primarily by activating VEGFR-2. We therefore in-CANCER CELL : MARCH 2005vestigated the effects of TNP-470 and caplostatin on the
VEGFR-2 signaling pathway in cultured EC. TNP-470 reduced
VPF/VEGF-induced phosphorylation of VEGFR-2 in human der-
mal microvascular endothelial cells (HMVEC-d) (Figure 6A) and
human umbilical vascular endothelial cells (HUVEC) (Figure 6B)
and did so at doses as low as 50 pg/ml (data not shown).
TNP-470 inhibited growth factor-induced proliferation of
HMVEC-d at concentrations as low as 1 pg/ml without causing
cytotoxicity (Figure 6C); only at concentrations above 1 g/ml
did TNP-470 become cytotoxic (below the basal cell prolifera-
tion in the absence of growth factors in the media). TNP-470
inhibited serum-induced proliferation (cytostatic effect) of U87
glioblastoma cells, but only at concentrations higher than 10
ng/ml (Figure 6C), and was only cytotoxic to tumor cells at con-
centrations higher than 100 g/ml. Thus, TNP-470 inhibited
VPF/VEGF-induced EC proliferation at concentrations four or-
ders of magnitude below that required to inhibit tumor cell
growth. This difference in sensitivity between tumor and endo-
thelial cells has been extensively investigated previously with
different cell lines (Milkowski and Weiss, 1999; Satchi-Fainaro
et al., 2004).
TNP-470 and caplostatin also inhibited downstream signal-
ing steps, including EC calcium influx ([Ca2+]i) (Figure 6D) nec-
essary for vascular permeability and proliferation (D.M. and
H.F.D., unpublished data), mitogen-activated protein kinase
(MAPK) phosphorylation (Figure 6G), and RhoA activation
(essential for VPF/VEGF-induced EC migration) (Figure 7).
Interestingly, TNP-470 and caplostatin also decreased Ca2+
influx induced by histamine (Figure 6E) and by PAF (Figure 6F).
These results suggest that TNP-470 does not inhibit perme-
ability solely through inhibition of VEGFR-2 phosphorylation,
because histamine and PAF act through different mechanisms.
TNP-470 inhibits EC migration and RhoA activation
We next examined the effect of TNP-470 on VPF/VEGF-induced
EC migration. Migration was assessed by counting the number
of cells that migrated through the membranes toward the
chemoattractant during a 4 hr period following 2 hr pretreat-
ment with free or conjugated TNP-470 (1 ng/ml). Treatment
with TNP-470 or caplostatin dramatically inhibited the chemo-
tactic migration response to VPF/VEGF by 68% (p = 0.00045)
and 87% (p = 0.000096), respectively (Figure 7A). In contrast,
cells treated with HPMA copolymer alone (at 1 g/ml TNP-470-
equivalent concentration) migrated similarly to untreated con-
trol HMVEC-d. TNP-470 also inhibited basal migration of
HMVEC-d cells in the absence of VPF/VEGF by 70% (p =
0.0023).
The RhoA superfamily of small GTPase has been shown to
play a key role in cell proliferation, shape change, and migra-
tion (Aspenstrom, 1999). RhoA and Rac1 are required for
VEGFR-2-mediated HMVEC-d migration (Zeng et al., 2002).
Therefore, we examined the possible role of RhoA in TNP-470’s
inhibition of VPF/VEGF-mediated HMVEC-d migration. VPF/
VEGF induced RhoA activation in HMVEC-d. TNP-470 signifi-
cantly decreased VPF/VEGF-activated RhoA (Figure 7B; densi-
tometrical quantification shown on the figure). These results
suggest that RhoA inhibition by TNP-470, at least in part, leads
to the inhibition of VPF/VEGF-induced migration of HMVEC-d.
We also tested the effect of TNP-470 on PAF-induced (Figure
7C) and histamine-induced (Figure 7D) RhoA activation, and
these were inhibited by TNP-470 and caplostatin as well.255
A R T I C L EFigure 6. Free and conjugated TNP-470 inhibit
VPF/VEGF-induced VEGFR-2 phosphorylation,
EC proliferation, Ca2+ influx, and MAPK in vitro
A and B: TNP-470 inhibits VEGFR-2 phosphoryla-
tion in HMVEC-d (A) and HUVEC (B). This Western
blot is representative of five experiments. Inhibi-
tion of VEGFR-2 phosphorylation ranged be-
tween 10% and 40%.
C: TNP-470 inhibited U87 glioblastoma (black
squares) and HMVEC-d (black circles) prolifera-
tion after 72 hr. The solid line represents the pro-
liferation of growth factor-induced cells, and
the dotted line represents cell proliferation in
the absence of growth factors. Data are ex-
pressed as mean ± SE.
D–F: Ca2+ influx in HMVEC-d induced by VEGF
(D), histmanine (E), or PAF (F) following treat-
ment with TNP-470 or caplostatin was reduced
compared to control.
G: TNP-470 inhibits VPF/VEGF-induced MAPK
phosphorylation in HMVEC-d. Densitometrical
analysis is presented as percentage of band in-
tensity compared to VEGF-stimulated control.To determine whether VPF/VEGF-induced permeability was
mediated by the RhoA pathway, we used Y27632, a pharmaco-
logical inhibitor of Rock, a downstream target of RhoA (Breslin
and Yuan, 2004). Rock is a kinase that has been implicated in
the formation of cell-cell junctions. Pretreatment of SCID mice
with Y27632 inhibited VPF/VEGF-induced and Escherichia coli
cytotoxic necrotizing factor-1 (CNF-1)-induced Evans blue-
albumin extravasation (Figure 7E). Activation of RhoA with
CNF-1 (Hopkins et al., 2003) was sufficient to promote extrava-
sation, because CNF-1 induced vessel leakage in the Miles
assay when injected intradermally (Figures 7E and 7F). This re-
sponse was inhibited by Y27632; thus, RhoA pathway ap-
peared to be a key mediator of VPF/VEGF-induced leakage.
Pretreatment of SCID mice with TNP-470 also inhibited
CNF-1-induced Evans blue-albumin extravasation (Figures 7E
and 7F). These results suggest that systemic in vivo inhibition
of RhoA causes inhibition of VPF/VEGF-induced vessel leaki-
ness and that TNP-470 inhibits vessel permeability through in-
hibition of RhoA activation.
Discussion
Tumor growth beyond a minimal size requires the generation
of new blood vessels, and for this reason recent attention has256been paid to antiangiogenesis as an approach to tumor ther-
apy. Tumors induce their new blood vessels by secreting angi-
ogenic cytokines, of which VPF/VEGF is arguably the most im-
portant. Some antiangiogenic agents have well-defined
targets, such as antibodies against VEGF or kinase inhibitors
directed against VEGF receptors (Kerbel and Folkman, 2002).
However, little is known about the mechanism of action of
other angiogenesis inhibitors, including TNP-470, caplostatin,
and angiostatin, that act directly on vascular endothelium. The
present study was designed to determine whether these inhibi-
tors affected steps in the angiogenic cascade other than EC
proliferation and to begin to define their molecular targets. We
report here that TNP-470, caplostatin, and angiostatin act, at
least in part, by inhibiting vascular permeability and EC migra-
tion, both intrinsic properties of pathological angiogenesis. We
also report initial studies that identify steps in the VPF/VEGF
signaling cascade that are affected by these agents.
Angiogenesis is a complex process that involves EC division,
migration, acquisition of pericytes, and other organizational
steps, not all of which have been defined. In addition, all forms
of pathological angiogenesis thus far identified are charac-
terized by vascular hyperpermeability, a state thought to result
from the expression of VPF/VEGF (Carmeliet and Collen, 2000;CANCER CELL : MARCH 2005
A R T I C L EFigure 7. Effect of VPF/VEGF and RhoA signaling on HMVEC migration in
vitro and on vessel permeability in vivo
A: HMVEC-d migration to VPF/VEGF. TNP-470 and caplostatin inhibited
basal and VPF/VEGF-induced migration of HMVEC-d. Data are expressed
as mean ± SD.
B–D: TNP-470 and caplostatin inhibited RhoA activation in HMVEC-d in-
duced by VPF/VEGF (B), PAF (C), or histamine (D). Densitometrical analysis
is presented as percentage of band intensity compared to VEGF-stim-
ulated control.
E: TNP-470 and Y27632 inhibited both VPF/VEGF- and CNF-1-induced ves-
sel permeability.CANCER CELL : MARCH 2005Although TNP-470 decreased permeability, our examination
F: Quantification of dye content in skin areas of the extravasation of Evans
blue dye at injection sites. TNP-470 and Y27632 reduced both VPF/VEGF-
and CNF-1-induced vessel permeability to Evans blue-albumin complex.
Data are expressed as mean ± SE.Matsumoto and Claesson-Welsh, 2001). Whether in tumors, in-
flammation, or wound healing, vascular hyperpermeability re-
sults in edema, clotting, and deposition of an extravascular
fibrin gel that provides a provisional matrix that favors angio-
genesis and mature stroma generation. Vascular hyperpermea-
bility also contributes to morbidity caused by inducing fluid ac-
cumulation in body cavities (e.g., pleural and peritoneal
cavities) and in the brain, where edema can become a life-
threatening complication (Ohnishi et al., 1990). Recently, pre-
vention of microvascular permeability by endothelial nitric
oxide synthase (eNOS) inhibition (see below) has been suc-
cessfully exploited as an approach to tumor therapy (Gratton
et al., 2003).
Given this background, we set out to determine whether the
potent angiogenesis inhibitors TNP-470, caplostatin, and angi-
ostatin had an effect on vascular permeability in tumors and
other examples of pathological angiogenesis. All six of the tu-
mors studied exhibited increased permeability, and we demon-
strated that TNP-470, caplostatin, and angiostatin effectively
inhibited the permeability response in five tumors. The lone ex-
ception was the U87 glioblastoma, a tumor that secretes un-
usually large amounts of VPF/VEGF. This finding might be ex-
plained by the dose-response data that show a threshold
above which TNP-470 is not able to inhibit VPF/VEGF-induced
permeability, at least under the conditions of our experiments.
Nonetheless, TNP-470 did inhibit the growth of the U87 tumor,
indicating that factors other than its antipermeability action
contribute to TNP-470’s effectiveness in preventing tumor
growth. TNP-470 was also effective in inhibiting the vascular
permeability characteristic of delayed hypersensitivity reac-
tions, which, like that of tumors, is thought to result from VPF/
VEGF expression.
Other experiments were performed to determine whether the
action of TNP-470 and angiostatin was specific for VPF/VEGF-
induced vascular permeability. We demonstrated that treat-
ment of mice with TNP-470 for as little as 24 hr suppressed
not only the permeability response to VPF/VEGF but also that
to PAF and histamine. We also demonstrated that animals
treated with TNP-470 were protected from the pulmonary
edema induced by IL-2. Taken together, these data indicate
that TNP-470, caplostatin, and angiostatin inhibit the vascular
permeability responses induced by a variety of agonists that
have been thought to act in different ways and by different sig-
naling pathways. Endostatin (M. Nomi, G. Schuch, N. Kilic, L.
Oliveira-Ferrer, R.S.-F., J. Weil, D.K.H., A. Atala, J.F., S. Soker,
and S. Ergun, personal communication) and endostatin pep-
tides (Tjin Tham Sjin et al., 2005) also inhibit vascular perme-
ability. It is possible, therefore, that these agents, and particu-
larly TNP-470 in its nontoxic polymeric form, will be of
therapeutic value not only in tumors but also in other circum-
stances where vascular permeability is a problem, e.g., inflam-
matory and hypersensitivity disorders, treatments with IL-2, ce-
rebral edema resulting from stroke, lymphedema, etc.257
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number and extent, interendothelial cell junctions appeared to
be normal, and fenestrae were not detectably increased in
TNP-470-treated animals. These data indicate that TNP-470
affects EC function but not structure. Consistent with these
results, we found no changes in junctional proteins of cultured
EC that were treated with TNP-470.
In addition to inhibiting vascular permeability and EC prolifer-
ation, TNP-470 also inhibited VPF/VEGF-induced EC migra-
tion. Recent work has done much to elucidate the signaling
steps by which VPF/VEGF mediates its several effects, and we
therefore sought to define the signaling events that were inhib-
ited by TNP-470. We found that TNP-470 inhibited VEGFR-2
phosphorylation as well as such downstream signaling steps
as MAPK phosphorylation and calcium influx. TNP-470 also
reduced VPF/VEGF-induced RhoA activation. RhoA is a major
player in cytoskeleton organization and in cellular tension gen-
eration (Hall, 1998; Ingber, 2002) and has an important role in
both EC proliferation and migration. Further, it has been sug-
gested that RhoA activation triggers Ca2+ entry via intracellular
store depletion, a precursor step to endothelial permeability
(Mehta et al., 2003). It has long been known that VPF/VEGF
stimulates transient accumulation of cytoplasmic calcium in
cultured EC (Brock et al., 1991). The increases in endothelial
cytosolic Ca2+ induced by VPF/VEGF, and also by PAF and
histamine, likely activate calcium/calmodulin-dependent en-
zymes such as eNOS. It has been previously shown that TNP-
470 inhibits nitric oxide production (Mauriz et al., 2003), and
nitric oxide has been implicated in VPF/VEGF-driven vascular
permeability (Fukumura et al., 2001). Activation of eNOS by
VPF/VEGF involves several pathways, including Akt/PKB,
calcium/calmodulin, and protein kinase C (Aoyagi et al., 2003;
Aramoto et al., 2004). Taking all of these facts together, we
have proposed in Figure 8 a model by which TNP-470 may act
as an antipermeability factor.
Experimental procedures
Materials
TNP-470 was kindly provided by Takeda Chemical Industries Ltd. (Japan).
HPMA copolymer precursor was from Polymer Laboratories (UK). Caplo-
statin was synthesized as previously described (Satchi-Fainaro et al., 2004).
VEGF165 was a gift from the NIH (Bethesda, CA). Bovine serum albumin
(BSA), dimethylformamide (DMF), formamide, Evans blue, histamine, and
oxazolone (4-Ethoxymethylene-2-phenyloxazolone) were from Sigma (St.
Louis, MO). PAF was from Biomol (Plymouth Meeting, PA), Vivacell 70 ml
dialysis system (10 kDa MW cutoff PES) was from VivaScience (USA).
Isoflurane was purchased from Baxter Healthcare Corporation (USA). Matri-
gel was from Becton Dickinson (USA), Avertin was from Fisher (USA), and
thalidomide was from Celgene (USA). Human and mouse VPF/VEGF quan-
tikine ELISA kits were purchased from R&D Systems Inc. (Minneapolis, MN).
Angiostatin was from EntreMed (USA), anti-Erb B-2 antibody (Herceptin)
was from Genentech (USA), and IL-2 was a gift from Dr. Steven A. Rosen-
berg (NIH). Rabbit polyclonal antibody against RhoA, anti-Flk-1 mouse mo-
noclonal, and an antibody against phosphorylated tyrosine (pTyr) mouse
monoclonal were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-Phospho-p44/42 MAPK mouse monoclonal antibody and anti-
p44/42 MAPK rabbit polyclonal antibody were from Cell Signaling Technol-
ogy, Inc. Y27632 was from Calbiochem (San Diego, CA). His-CNF1 plasmid
was a gift from Melody Mills (Uniformed Services University of Health Sci-
ences, MD) and was expressed in Escherichia coli; recombinant CNF-1 was
purified with the QIAGEN kit. Glutathione-S-transferase (GST)-Rhotekin Rho
binding domain (TRBD) fusion protein was provided by Dr. Martin Schwartz
(Scripps Institute) (Ren et al., 1999).258Figure 8. Schematic model for proposed mechanism of TNP-470 inhibition
of vessel permeability
TNP-470 inhibits migration and proliferation of EC and prevents VEGF-, PAF-,
and histamine-induced permeability. VEGF, PAF, and histamine enhance
vascular leakage by opening of interendothelial junctions, endothelial fe-
nestration, generation of transendothelial gaps, and transcytotic vesicles
including VVO. Pretreatment with TNP-470 decreases the leakage via
transcytotic vesicles. TNP-470 inhibited VEGFR-2 phosphorylation, [Ca2+]i,
and RhoA activation in vascular endothelium. This model suggests that
TNP-470 transforms angiogenic and hyperpermeable vessels to a less leaky
morphologic phenotype.Cell culture
Tumor cells (A2058 human melanoma, U87 human glioblastoma, BXPC3,
LLC, MCF-7, MDA-MB-231) were obtained from the American Type Culture
Collection (Manassas, VA). Cells were cultured as previously described
(Satchi-Fainaro et al., 2004). BCE cells were isolated and maintained as
described (Folkman et al., 1979). HMVEC-d and HUVEC were obtained from
Cambrex (Walkersville, MD) and grown according to the manufacturer’s pro-
tocol in EGM-2 MV medium or EGM, respectively, supplemented with bullet
kits (Cambrex).
Mice
C57Bl/6J mice were purchased from Jackson Laboratories (USA), and CB-
17 SCID mice were purchased from Massachusetts General Hospital (USA).
All animal procedures were performed in compliance with Boston Children’s
Hospital guidelines and protocols approved by the Institutional Animal Care
and Use Committee.
Miles vascular permeability assay
SCID mice were injected subcutaneously (s.c.) with TNP-470 or caplostatin
(30 mg/kg TNP-470-equivalent concentration) for 3 days, with Y27632 (50
nM s.c.) for 11 days, with angiostatin (200 mg/kg/day s.c.) for 5 days, or
with saline (250 l s.c.) for 5 days (n = 12 mice/group) before the Miles
assay was performed (Claffey et al., 1996; Miles and Miles, 1952; Streit et
al., 2000). Briefly, Evans blue dye (100 l of a 1% solution in 0.9% NaCl)
was injected intravenously (i.v.) into mice. After 10 min, 50 l of human
VEGF165 (1 ng/l), PAF (100 M), CNF-1 (100 ng), histamine (1.2 g/ml), or
PBS was injected intradermally into the preshaved back skin. After 20 min,
the animals were euthanized, and an area of skin that included the entire
injection site was removed. Evans blue dye was extracted from the skin by
incubation with formamide for 5 days at room temperature, and the absor-
bance of extracted dye was measured at 620 nm. In addition, in order to
test the effect of TNP-470 on blood volume and flow we measured dye
accumulation in the uninjected flank skin of mice treated as above with
TNP-470 or saline. Five minutes later, we performed punch biopsies of flank
skin from both sets of mice and extracted these with formamide as above.
The unpaired Student’s t test was used for statistical analysis.
Tissue processing for electron microscopy
SCID mice were treated for 3 days with TNP-470 or saline as above, follow-
ing which anionic ferritin was injected as tracer i.v.; 50 l of human VEGF165
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After 15 min, animals were euthanized. Skin test and control sites were
excised and fixed by immersion and processed for electron microscopy as
previously described (Dvorak et al., 1996; Feng et al., 1996).
Endothelial junctional proteins
BCE were cultured on glass coverslips in a 24-well plate (200,000 cells/
well) in Dulbecco’s modified Eagle’s medium (DMEM) + 10% bovine calf
serum (BCS) + 3 ng/ml bFGF in the presence or absence of TNP-470 (1 ng/
ml) for 3 days. Thereafter, PAF (100 M) or VEGF (50 ng/ml) was added for
20 min, and the cells were fixed in paraformaldehyde 4% for 10 min and in
methanol for 5 min at room temperature. Fixed cells were incubated over-
night with polyclonal antibodies to occludin, claudin, ZO-1, or VE-cadherin
or a monoclonal antibody to β-catenin (Zymed Laboratories, South San
Francisco, CA). The staining was subsequently developed with FITC-conju-
gated secondary antibodies and photographed using a fluorescent micro-
scope.
DTH reactions
DTH reactions were induced in the flank skin of 8-week-old C57Bl/6J male
mice (n = 5) as previously described (Dvorak et al., 1984). Mice were sensi-
tized by topical application of 2% oxazolone solution in vehicle (acetone:ol-
ive oil, 4:1 vol/vol), to the shaved abdomen (50 l) and to each paw (5 l).
Mice were treated with TNP-470 (30 mg/kg s.c.) for 3 days beginning on
day 2, and at 5 days the right ears were challenged by topical application
of 10 l of a 1% oxazolone solution; the left ears were treated with vehicle
alone. Ear thickness was then measured daily for 7 days as a measure of
inflammation intensity (Gad et al., 1986). Statistical analysis was performed
using the unpaired Student’s t test. Some mice from each experimental
group were euthanized 24 hr after oxazolone challenge (n = 5 per group).
One half of each ear was fixed in 10% formalin and processed for H&E-
stained paraffin sections. The other half was embedded in OCT compound
(Sakura Finetek, Torrance, CA) and snap frozen in liquid nitrogen for immu-
nohistochemical staining of 5 m cryostat sections using a Vecstatin avidin-
biotin detection system (Vector Labs, Burlingame, CA) with rat monoclonal
antibodies against mouse CD31 (dilution 1:250; Pharmingen, San Diego, CA).
IL-2-associated pulmonary edema
C57Bl/6J male mice were injected with TNP-470 (30 mg/kg daily) or saline
s.c. for 3 days. Then, mice were injected with IL-2 (1.2 × 106 units/100 l)
or saline intraperitoneally (i.p.) three times a day for 5 days. At termination,
mice were euthanized, and lungs were dissected, weighed, fixed, and pro-
cessed for H&E staining.
Tumor vascular permeability
Female SCID mice (~8 weeks, ~20 g) were inoculated s.c. with 5 × 106
viable U87 glioblastoma, A2058 human melanoma, or BXPC3 pancreas ad-
enocarcinoma cells. Female nu/nu mice were inoculated with 1 × 106 MCF-7
or MDA-MB-231 breast carcinoma cells in the mammary fat pad. C57Bl/6J
were inoculated s.c. with 5 × 106 LLC cells. When tumors reached a volume
of approximately 100 mm3, mice were injected s.c. with free TNP-470 (as
above) or caplostatin (30 mg/kg TNP-470-equivalent concentration) for 3
days, angiostatin (200 mg/kg s.c.) for 5 days, or saline (250 l s.c.) for 5
days (n = 10). Evans blue dye was then injected i.v., and dye was extracted
and assessed as above. Also, VPF/VEGF levels were measured in plasma
and in tumors (n = 5 from each group). Tumors (n = 5 per group) were
dissected, weighed, and bisected. Half of each tumor was placed in forma-
lin, and half was analyzed for VPF/VEGF protein by ELISA (see below). For-
malin-fixed tumors were processed for H&E sections as above and for
CD31, SMA, and PCNA staining according to the manufacturer’s instruc-
tions.
To determine the ability of TNP-470 to inhibit the permeability response
induced by increasing doses of VPF/VEGF, 8-week-old C57Bl/6J mice were
treated with TNP-470 (30 mg/kg/day s.c. for 3 days) or with saline. Evans
blue (100 l; 1%) was injected i.v., and after 10 min VPF/VEGF was injected
intradermally at increasing concentrations (from 2.5 × 10−5 to 250 ng/ml).
Twenty minutes later, punch biopsies of flank skin from both sets of mice
were taken and processed as above.CANCER CELL : MARCH 2005ELISA assays for VPF/VEGF
Blood drawn from tumor-bearing mice was centrifuged, and plasma was
collected. Solid tumors were homogenized and resuspended in lysis buffer.
In addition, tumor cells were plated at 500,000 cells per well (six-well
plates), and conditioned medium from cells was collected 48 hr later. Levels
of VPF/VEGF in plasma, tumors, and culture supernatants were determined
in duplicate samples by ELISA (R&D Systems, MN).
Cell proliferation assay
HMVEC-d cells were plated at 15,000 cells/ml onto gelatinized 24-well cul-
ture plates in EBM-2 supplemented with 5% fetal bovine serum (FBS) and
incubated for 24 hr (37°C; 5% CO2). Medium was replaced with complete
media (serum and growth factors; EGM-2 MV). U87 glioblastoma cells were
plated at 5000 cells/ml in DMEM supplemented with 10% FBS and incu-
bated for 24 hr (37°C; 5% CO2). Medium was replaced with DMEM and
10% FBS. Both cell types were challenged with free or conjugated TNP-
470 (0.01 pg/ml to 1 mg/ml TNP-470-equivalent concentration). Control
cells were grown with or without growth factors. Both cell types were incu-
bated for 72 hr, followed by trypsinization and resuspension in Hematall
(Fisher Scientific, Pittsburgh, PA), and counted in a Coulter counter.
Cell migration assay
Cell migration was performed as previously described (Short et al., 2005)
with the following modifications: suspended HMVEC-d were treated with
free or conjugated TNP-470 at equivalent concentrations of 1 ng/ml, and
cells were added to the upper chamber of the transwell for a 2 hr incubation
prior to migration to VEGF.
VEGFR-2 phosphorylation
Serum-starved (0.1% FBS in EBM-2 media for 24 hr) HMVEC-d or HUVEC
were treated with 5 ng/ml TNP-470 and caplostatin at 37°C for 2 hr and
then stimulated with 10 ng/ml of VEGF for 5 min. Stimulation was stopped
by adding cold PBS. Cells were lysed with cold precipitation buffer (20 mM
Tris-HCl [pH 7.5], 0.15 M NaCl, 1% Triton X-100, 1 mM PMSF, 1 mM
Na3VO4, 1 mM EGTA, 1 g/ml leupeptin, 0.5% aprotinin, and 2 g/ml pep-
statin A). Lysate protein (500 g) was incubated with 1 g of antibody
against VEGFR-2 for 2 hr, then with 50 µl of protein A-conjugated agarose
beads at 4°C for 3–4 hr. After the beads were washed with precipitation
buffer, immunoprecipitates were resuspended in 2× SDS sample buffer for
Western blot analysis with an antibody against phosphorylated tyrosine
(pTyr).
RhoA activation assay
pGST-TRBD bacteria were grown and induced with isopropyl-thiogalacto-
side. The bacterial suspensions were divided into 50 ml aliquots and then
harvested and frozen at −80°C. To prepare the GST-TRBD beads, each
aliquot of frozen bacteria was resuspended in 2 ml of cold PBS, and then
20 µl of 1 M dithiothreitol (DTT), 20 µl of 0.2 M PMSF, and 40 µl of 50 mg/
ml lysozyme were added. The sample was incubated on ice for 30 min.
Next, 225 µl of 10% Triton X-100, 22.5 µl of 1 M MgCl2, and 22.5 µl of 2000
KU/ml DNase were added, and the sample was incubated on ice for another
30 min. The supernatant was collected and incubated with 100 µl glutathi-
one-coupled Sepharose 4B beads (Pharmacia Biotech) at 4°C for 45 min.
The beads were then washed with bead-washing buffer (PBS with 10 mM
DTT and 1% Triton X-100) and resuspended in the same buffer to give a
50% bead slurry.
HMVEC-d cells serum-starved for 24 hr were treated with 5 ng/ml TNP-
470 at 37°C for 2 hr and then stimulated with 10 ng/ml of VEGF, PAF (10
nM), or histamine (100 mM) for 5 min. Stimulation was stopped by adding
cold PBS. Cells were lysed with lysis buffer (150 mM NaCl, 0.8 mM MgCl2,
5 mM EGTA, 1% IGEPAL, 50 mM HEPES [pH 7.5], 1 mM PMSF, 10 µg/
ml leupeptin, and 10 µg/ml aprotinin). The supernatant was isolated and
incubated with 50 µl of GST-TRBD beads at 4°C for 45 min. Protein bound
to beads was washed with AP wash buffer (50 mM Tris-HCl [pH 7.2], 1%
Triton X-100, 150 mM NaCl, 10 mM MgCl2, 1 mM PMSF, 10 µg/ml leupeptin,
and 10 µg/ml aprotinin) and analyzed by SDS-PAGE with an antibody
against RhoA (Santa Cruz Biotechnology, CA).
Phosphorylation of MAPK
Serum-starved HMVEC-d were treated with 5 ng/ml TNP-470 at 37°C for 2
hr and then stimulated with 10 ng/ml of VEGF for 5 min. Stimulation was259
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Cellular extracts (20 g) were immunoblotted with an antibody against
phosphorylated MAPK (p-MAPK) (Cell Signaling Technology Inc.). The blot
was stripped and reprobed with an antibody against MAPK to confirm equal
protein loading.
Ca2+ assays
Serum-starved confluent HMVEC-d were detached with 4 ml of collagenase
solution (0.2 mg/ml collagenase, 0.2 mg/ml soybean trypsin inhibitor, 1 mg/
ml BSA, and 2 mM EDTA in PBS) at 37°C for 30 min on a 10 cm dish. Cells
were centrifuged, and pellets were washed with 2 ml of Ca2+ buffer (5 mM
KCl, 140 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 5.6 mM glucose, 0.1% BSA,
0.25 mM sulfinpyrazone, and 10 mM HEPES [pH 7.5]) and then resus-
pended in 2 ml of the same buffer containing 5 ng/ml TNP-470. The cells
were incubated at 37°C for 2 hr in suspension. During the last 30 min of
incubation, 1 µg/ml Fura-2-AM (acetoxymethyl ester derivative of Fura 2)
and 0.02% pluronic F-127 were added to the suspension. Cells (106) were
collected and resuspended in 2 ml Ca2+ buffer for VPF/VEGF (10 ng/ml),
PAF (20 nM), or histamine (100 mM) stimulation, while the tubes were
rocked. Intracellular Ca2+ concentrations were measured with the Delta-
Scan Illumination System (Photon Technology International Inc.) using Fe-
lix software.
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